The Global Immunization Working Group of the National Vaccine Advisory Committee

Update on Working Group Progress
NVAC Meeting
12 September 2012

GIWG Co-Chairs
Phil LaRussa, MD
Amy Pisani, MS
Charge

Purpose:
• To review US government global vaccination efforts to ensure that HHS is on track to fulfill responsibilities and meet the goals and objectives outlined in Goal 5 of the National Vaccine Plan and the HHS Global Health Strategy

Charge:
• To review the role of HHS in global vaccination, the effects of global vaccination on global populations, the effects of global vaccination on US populations

• To recommend how HHS can best continue to contribute, consistent with its newly established Global Health Strategy and Goal 5 of the National Vaccine Plan

• To recommend how to best communicate this information to decision makers and the general public to ensure continued sufficient resources for the global vaccination effort

Adopted:
• NVAC adopted this resolution at the February 2012 meeting

• The Global Immunization Working Group was formed in April 2012 to address charge
Membership

NVAC Members
Walt Orenstein - NVAC chair
Phil LaRussa – GIWG co-chair
Amy Pisani – GIWG co-chair
Charles Mouton
Thomas Stenvig
Clem Lewin
Seth Hetherington
Jim Mason

Federal Ex Officio Members
Steve Cochi – CDC
Theresa Fin – FDA
Cyril Gay – USDA/APHIS
Marion Gruber - FDA
Rick Hill – USDA/APHIS
Jeff Kelman- CMS
Philip Krause - FDA
Iris Mabry-Hernandez- AHRQ
Richard Martinello- VA
Justin Mills- HRSA
Barbara Mulach- NIH
Jane Seward- CDC
Angela Shen - USAID
Murray Trostle- USAID
Diana Parzik- DoD
Holly Wong - OGA

Liaison Representatives
Alan Hinman – Task Force for Global Health
Steve Landry – Bill and Melinda Gates Foundation
Nina Schwalbe- GAVI Alliance
Andrea Gay – Unites Nations Foundation
Bonnie Maldonado – American Academy of Pediatrics
Peter Strebel – WHO, Dept. of Immunization, Vaccines, and Biologicals
Armin Fidler – World Bank, Health, Policy, and Strategy
Maritel Costales – UNICEF, Immunization Team
Akira Homma – Developing Countries Vaccine Manufacturers Network
Mahima Datla – Developing Countries Vaccine Manufacturers Network

NVPO
Mark Grabowsky – Designated Federal Official
Jennifer Gordon
Claire Slesinski

Special Assistants
Katy Seib – Special Assistant to the NVAC chair
Stacy Kramer – Special Assistant to GIWG chairs
# Working Group Progress

<table>
<thead>
<tr>
<th>DATE</th>
<th>Working Group Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 24</td>
<td>Role of the USG in Global Immunizations - <em>Steve Cochi/ CDC</em></td>
</tr>
<tr>
<td>May 29</td>
<td>Global Immunization: Impact on US Vaccine Preventable Diseases and Public Health - <em>Jane Seward/ CDC</em></td>
</tr>
<tr>
<td>June 06</td>
<td>June NVAC Meeting – Update to NVAC</td>
</tr>
<tr>
<td>June 26</td>
<td>Strengthening the HHS Profile – <em>Elizabeth Gore and Peter Yeo/ Shot@Life, UN Foundation</em></td>
</tr>
<tr>
<td>July 17</td>
<td>NIH’s Role in Global Immunizations – <em>Barbara Mulach/ NIH</em></td>
</tr>
<tr>
<td></td>
<td>FDA/CBER Presentation on Global Vaccines - <em>Phil Krause/ FDA</em></td>
</tr>
<tr>
<td>August 07</td>
<td>USAID Global Immunization Program – <em>Murray Trostle/ USAID</em></td>
</tr>
<tr>
<td>August 23</td>
<td>Meeting to Discuss DRAFT recommendations</td>
</tr>
<tr>
<td>September 11</td>
<td>Meeting to discuss input on DRAFT recommendations and DRAFT report</td>
</tr>
<tr>
<td>September 12</td>
<td>September NVAC Meeting – Update to NVAC</td>
</tr>
</tbody>
</table>
Proposed Areas of Focus for Recommendations

• Financing global immunization

• Strengthening HHS Policy Leadership, Coordination, and Partnerships

• Research and Development

• Global Regulatory Issues

• Health Systems and Vaccine Delivery

• US Response Efforts to Vaccine-Preventable Diseases of Global Health Importance

• Communications/ Risk communications on Vaccine Safety
1. Who is the audience of the report?
   - ASH/HHS
   - Congress?
   - USG Immunization Policy Makers?

2. Should the WG recommendations focus on defending current HHS activities and argue for maintaining current funding or should they also advocate for additional financial support of global immunizations?

3. Among the issues the report will address, are there some which should receive higher priority than others?

4. The report will provide a current landscape analysis of HHS activities. Should it also discuss future needs?
Discussion